248 related articles for article (PubMed ID: 23716037)
1. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.
Nakamura T; Shiraki M; Fukunaga M; Tomomitsu T; Santora AC; Tsai R; Fujimoto G; Nakagomi M; Tsubouchi H; Rosenberg E; Uchida S
Osteoporos Int; 2014 Jan; 25(1):367-76. PubMed ID: 23716037
[TBL] [Abstract][Full Text] [Related]
2. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
Bone HG; McClung MR; Roux C; Recker RR; Eisman JA; Verbruggen N; Hustad CM; DaSilva C; Santora AC; Ince BA
J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
[TBL] [Abstract][Full Text] [Related]
3. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.
Bone HG; Dempster DW; Eisman JA; Greenspan SL; McClung MR; Nakamura T; Papapoulos S; Shih WJ; Rybak-Feiglin A; Santora AC; Verbruggen N; Leung AT; Lombardi A
Osteoporos Int; 2015 Feb; 26(2):699-712. PubMed ID: 25432773
[TBL] [Abstract][Full Text] [Related]
4. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
5. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
[TBL] [Abstract][Full Text] [Related]
6. Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.
Rizzoli R; Benhamou CL; Halse J; Miller PD; Reid IR; Rodríguez Portales JA; DaSilva C; Kroon R; Verbruggen N; Leung AT; Gurner D
Osteoporos Int; 2016 Jun; 27(6):2099-107. PubMed ID: 26879200
[TBL] [Abstract][Full Text] [Related]
7. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
Brixen K; Chapurlat R; Cheung AM; Keaveny TM; Fuerst T; Engelke K; Recker R; Dardzinski B; Verbruggen N; Ather S; Rosenberg E; de Papp AE
J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
[TBL] [Abstract][Full Text] [Related]
8. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
Koldkjær Sølling AS; Harsløf T; Langdahl B
Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
[TBL] [Abstract][Full Text] [Related]
9. Potential role of odanacatib in the treatment of osteoporosis.
Ng KW
Clin Interv Aging; 2012; 7():235-47. PubMed ID: 22866001
[TBL] [Abstract][Full Text] [Related]
10. Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis.
Binkley N; Orwoll E; Chapurlat R; Langdahl BL; Scott BB; Giezek H; Santora AC
Osteoporos Int; 2021 Jan; 32(1):173-184. PubMed ID: 33200257
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
12. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
[TBL] [Abstract][Full Text] [Related]
13. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.
Nakamura T; Matsumoto T; Sugimoto T; Shiraki M
Osteoporos Int; 2012 Mar; 23(3):1131-40. PubMed ID: 21927920
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial.
Binkley N; Bone H; Gilligan JP; Krause DS
Osteoporos Int; 2014 Nov; 25(11):2649-56. PubMed ID: 25027109
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S; Delmas P
Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
[TBL] [Abstract][Full Text] [Related]
16. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
[TBL] [Abstract][Full Text] [Related]
17. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
Shiraki M; Fukunaga M; Kushida K; Kishimoto H; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H
Osteoporos Int; 2003 May; 14(3):225-34. PubMed ID: 12730746
[TBL] [Abstract][Full Text] [Related]
18. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
[TBL] [Abstract][Full Text] [Related]
19. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
20. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
Eisman JA; Bone HG; Hosking DJ; McClung MR; Reid IR; Rizzoli R; Resch H; Verbruggen N; Hustad CM; DaSilva C; Petrovic R; Santora AC; Ince BA; Lombardi A
J Bone Miner Res; 2011 Feb; 26(2):242-51. PubMed ID: 20740685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
